MINYANVILLE ORIGINAL It doesn’t look like Vivus’
(NASDAQ:VVUS) diet pill is going to be approved in Europe anytime soon and that may be bad for a potential takeover of the company, according to at least one analyst.
Vivus said Friday
that a panel considering approval of the company’s weight-loss drug is likely to issue an opinion against recommending EU clearance for sale of the product. Last week, Vivus said
it began selling Qsymia, the first new diet pill in the US in 13 years. Vivus also was hoping to sell the drug in Europe under the name Qsiva.
Cowen & Co. analyst Simos Simeonidis said the biggest impact of the news is that it may hinder a possible takeover of the company. Some investors believe Vivus is a potential acquisition candidate because, unlike two of its closest rivals, it doesn’t have a big pharmaceutical company partner to help sell its drugs. Arena Pharmaceuticals
(NASDAQ:ARNA) and Orexigen Therapeutics
(NASDAQ:OREX) both have partners for their diet-pill marketing and development. Arena won US approval for its drug, Belviq, this summer but hasn’t started selling it. Orexigen is still testing its unapproved diet pill for safety.
“The largest impact on Vivus is that it may remove at least some of the acquisition premium assigned by some investors since lack of ex-US revenue makes an acquisition by a large pharma less likely, albeit possible,” Simeonidis says.
Shares of Vivus fell 11% Friday on the news. The stock fell 2% to $20.65 in early trading Monday morning. The shares more than doubled this year.
(See How Much Can Vivus, Arena Pharma Charge for Diet Pills?
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.